Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
Achillion partners with J&J to develop hepatitis C drugs

Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

Published
20 May 2015
From
Reuters
Is Gilead Sciences Its Own Worst Enemy?

Gilead's science is so good that it's actually destroying the company's business. Pharma companies, like most other businesses, make the bulk of their money through repeat business. Gilead, however, is doing something really no other drugmaker is doing -- namely curing patients of devastating infectious diseases.

Published
20 May 2015
From
Motley Fool
Glaxo drops plans to float 'gamechanging' HIV drugs arm, favouring in-house profits

The chief executive Andrew Witty declared prospects for its HIV drugs arm had improved dramatically in the past few months, thanks to a rapid increase in sales and some new forms of medicine being on the cusp of major breakthroughs.

Published
07 May 2015
From
The Independent
Glaxo Abandons HIV-Unit Spinoff Plan, Reduces Capital Payout

GlaxoSmithKline Plc shares rose as the U.K.’s biggest drug company abandoned plans to spin off its flourishing HIV-drugs unit and reduced funds to be returned to shareholders, retaining capital for bolstering growth. The decision to retain its full stake in ViiV Healthcare, an HIV joint venture with Pfizer Inc., reflects the unit’s “very positive outlook,” Glaxo said.

Published
06 May 2015
From
Bloomberg
US guidelines shift to integrase-based combinations for first-line treatment: Atripla relegated due to side effects

The rationale for dropping Atripla is due to concerns about the tolerability of efavirenz, especially the high rate of central nervous system related toxicities. Although this has been a long-standing community concern, DHHS guidelines have consistently recommended efavirenz in previous editions. This tolerability statement is made in the year that efavirenz comes off patent.

Published
06 May 2015
From
i-Base
Civil Society Groups Tell UNITAID: Support access mechanisms led by civil society, not the pharmaceutical industry

Letters from global groups express deep concerns about the Medicines Patent Pool’s entry into hepatitis C treatment.

Published
05 May 2015
From
Hep C Coalition
Gilead’s Gaffe Leads Drugmakers to Pledge More Openness on Price

Drugmakers worried about a backlash over soaring drug prices are increasingly talking with insurers ahead of time about paying for new therapies that could cost six figures a year.

Published
05 May 2015
From
Bloomberg
Egypt opens first factory for locally produced Sovaldi

Egypt's health minister said Hepatitis C is "one of the most dangerous threats to Egypt", on Sunday during the opening ceremony of a factory for the local production of Hepatitis C medication Sovaldi.

Published
05 May 2015
From
News Egypt
Gilead first-quarter profit doubles on strong hepatitis C drug sales

Gilead Sciences Inc on Thursday said its quarterly profit nearly doubled, driven by strong sales of its hepatitis C drugs, as it topped Wall Street estimates. Gilead signaled that, with its hepatitis C franchise established, it is a good time for the company to consider business development opportunities. "We want to stick very closely to therapeutic areas we are in today," Gilead Chief Operating Officer John Milligan said on a conference call.

Published
05 May 2015
From
Reuters
Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie

Merck has previously stated that it will seek approval for the grazoprevir/elbasvir combination pill in the middle of the year. If approved by the end of the year or in early 2016 -- and there's probably little risk the therapy won't be approved -- Merck's dilemma will be finding a way to grab market share for a new hepatitis C therapy without any clinical or convenience advantages over the existing competition.

Published
09 April 2015
From
The Street
← First12345...76Next →

Filter by country